KRAS and breast carcinoma: Furthermore, there was an association between diminished survival and alterations less frequently detected in breast cancer, encompassing CTCF, ERBB2, FGFR, GATA3, KRAS, MAPK, NOTCH2, PTEN, and TOP1 (hazard ratio, 1.82; 95% CI, 1.26-2.39; P < .001).